Cargando…

Targeting BRAF V600E in metastatic colorectal cancer: where are we today?

Colorectal cancer (CRC) is the second most frequent cause of direct cancer death worldwide. The study of the molecular state of oncogenes has predictive and prognostic value in metastatic CRC (mCRC). The B-raf proto-oncogene (BRAF) gene mutation represents the 8%–12% of all mutations in mCRC. The BR...

Descripción completa

Detalles Bibliográficos
Autores principales:	Guerrero, Rodrigo Motta, Labajos, Veronica Arnao, Ballena, Sophia Lozano, Macha, Carlos Aliaga, Lezama, Miguel Sotelo, Roman, Cristian Pacheco, Beltran, Paola Montenegro, Torrejon, Alejandro Figueroa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cancer Intelligence 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9934973/ https://www.ncbi.nlm.nih.gov/pubmed/36819812 http://dx.doi.org/10.3332/ecancer.2022.1489

Ejemplares similares

Where's the CASE (Patient) Today?
por: Kaul, Viren
Publicado: (2008)

BRAF(V600E) protein expression and outcome from BRAF inhibitor treatment in BRAF(V600E) metastatic melanoma
por: Wilmott, J S, et al.
Publicado: (2013)

BRAF V600E Inhibitor (Vemurafenib) for BRAF V600E Mutated Low Grade Gliomas
por: Del Bufalo, Francesca, et al.
Publicado: (2018)

Leishmaniasis Vaccine: Where are We Today?
por: Kedzierski, Lukasz
Publicado: (2010)

Pathology of thymoma—where are we today?
por: Soomro, Irshad Nabi
Publicado: (2020)

Ocular tuberculosis: Where are we today?
por: Testi, Ilaria, et al.
Publicado: (2020)

Refractive surgery: Where are we today?
por: Sachdev, Mahipal S
Publicado: (2020)

The role of BRAF V600 mutation in melanoma
por: Ascierto, Paolo A, et al.
Publicado: (2012)

Acquired resistance to BRAF inhibition in BRAF(V600E) mutant gliomas
por: Yao, Tsun-Wen, et al.
Publicado: (2016)

Small molecules against B-RAF (BRAF) Val600Glu (V600E) single mutation
por: Zaharie, Florin, et al.
Publicado: (2015)

Robotic Radical Cystectomy: Where are We Today, Where will We be Tomorrow?
por: Richards, Kyle A., et al.
Publicado: (2010)

HIV-2 Infection: Where Are We Today?
por: Ingole, Nayana A., et al.
Publicado: (2013)

Laboratory Information System – Where are we Today?
por: Lukić, Vera
Publicado: (2017)

Preimplantation Genetic Testing: Where We Are Today
por: Greco, Ermanno, et al.
Publicado: (2020)

Cryopreservation of single-sperm: where are we today?
por: Liu, Shasha, et al.
Publicado: (2020)

Immunohistochemical BRAF V600E Expression and Intratumor BRAF V600E Heterogeneity in Acral Melanoma: Implication in Melanoma-Specific Survival
por: Ito, Takamichi, et al.
Publicado: (2020)

BRAF V600K vs. BRAF V600E: a comparison of clinical and dermoscopic characteristics and response to immunotherapies and targeted therapies
por: Zengarini, Corrado, et al.
Publicado: (2022)

Psychopharmacology Today: Where are We and Where Do We Go From Here?
por: Schwartz, Thomas L.
Publicado: (2010)

BRAF Inhibition in BRAF(V600)-Mutant Gliomas: Results From the VE-BASKET Study
por: Kaley, Thomas, et al.
Publicado: (2018)

Differential responsiveness to BRAF inhibitors of melanoma cell lines BRAF V600E-mutated
por: Al Hashmi, Muna, et al.
Publicado: (2020)

Tissue-Agnostic Activity of BRAF plus MEK Inhibitor in BRAF V600–Mutant Tumors
por: Adashek, Jacob J., et al.
Publicado: (2022)

Retrograde intra-renal surgery: Where are we today?
por: Chibber, Percy Jal
Publicado: (2008)

Magnetic Resonance Coronary Angiography: Where Are We Today?
por: Chiribiri, Amedeo, et al.
Publicado: (2013)

Pneumococcal vaccination in older persons: where are we today?
por: Van Buynder, Paul, et al.
Publicado: (2018)

Scleral surgery for the treatment of presbyopia: where are we today?
por: Hipsley, AnnMarie, et al.
Publicado: (2018)

Precision diabetes: Where do we stand today?
por: Mohan, Viswanathan, et al.
Publicado: (2018)

Oesophageal Adenocarcinomas: Where Do We Stand Today?
por: Karstens, Karl-Frederick, et al.
Publicado: (2020)

High frequency of BRAF V600E mutations in ameloblastoma
por: Kurppa, Kari J, et al.
Publicado: (2014)

BRAF V600E-Negative Hairy Cell Leukaemia
por: Langabeer, Stephen E., et al.
Publicado: (2013)

MEK inhibitors in non-V600 BRAF mutations and fusions
por: Johnson, Douglas B., et al.
Publicado: (2020)

Targeted Therapy for Melanomas Without BRAF V600 Mutations
por: Menzer, Christian, et al.
Publicado: (2022)

Intrathoracic synovial sarcoma with BRAF V600E mutation
por: Russo, Ida, et al.
Publicado: (2023)

BRAF Non-V600 Mutations in Metastatic Colorectal Cancer
por: Liu, Junjia, et al.
Publicado: (2023)

Emotions and motivation in mathematics education: Where we are today and where we need to go
por: Schukajlow, S., et al.
Publicado: (2023)

BRAF V600E mutation and BRAF VE1 immunoexpression profiles in different types of glioblastoma
por: Tosuner, Zeynep, et al.
Publicado: (2018)

BRAF Inhibitors for BRAF V600E Mutant Colorectal Cancers: Literature Survey and Case Report
por: Peker, Yasar Subutay, et al.
Publicado: (2018)

BRAF inhibitors promote intermediate BRAF(V600E) conformations and binary interactions with activated RAS
por: Röck, Ruth, et al.
Publicado: (2019)

LGG-55. OUTCOME OF BRAF V600E PEDIATRIC GLIOMAS TREATED WITH TARGETED BRAF INHIBITION
por: Nobre, Liana, et al.
Publicado: (2020)

BRAF, MEK and EGFR inhibition as treatment strategies in BRAF V600E metastatic colorectal cancer
por: Ros, Javier, et al.
Publicado: (2021)

BRAF inhibitors in BRAF V600E-mutated ameloblastoma: systematic review of rare cases in the literature
por: Ebeling, Marcel, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_4585et8s5had7kanj09ivu2sef